Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Washington University School of Medicine
With
National Cancer Institute (NCI)
The overall goal of this project is determination of the role of PET in patients with newly diagnosed medium- and high-risk prostate cancer in whom the standard clinical and imaging workup is negative. Thus, the incremental value of PET will be determined in this important group.
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Newly diagnosed prostate cancer
Has completed conventional staging examinations, including biopsy with Gleason score, CT scan of the abdomen and pelvis, and whole-body bone scintigraphy AND conventional staging examinations negative
Candidate for curative radical prostatectomy OR curative radiotherapy OR staging lymphadenectomy prior to surgery
Deemed to be at medium or high risk for recurrence after initial curative treatment, as defined by 1 of the following criteria:
* Gleason score 7 AND prostate-specific antigen (PSA) 10-20 ng/mL
* Gleason score ≥ 8 AND PSA \< 10 ng/mL
* Gleason score ≥ 8 AND PSA \> 10 ng/mL
* Any Gleason score AND PSA \> 20 ng/mL
Exclusion Therapy:
Not a candidate for treatment by surgery or radiation therapy with curative intent
Inability to give informed consent
Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of other cancer present within the last 5 years
Clareo Health | Positron Emission Tomography in Prostate Cancer
